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The incidence of Candida bloodstream infection (BSI) has increased during 
the past decades. Species distribution is changing worldwide, and non-albicans 
Candida spp. are becoming more prevalent. Acquired resistance to antifungal agents 
has been documented in several reports. The aim of our study was to assess the epi-
demiology and antifungal susceptibility of Candida isolates from BSI at our insti-
tute. The incidence of Candida BSI increased during the fi rst four years of our inves-
tigation, from 1.7 to 3.5 episodes / 10 000 admissions, then dropped to 2.66 episodes 
/ 10 000 admissions in the last year. The most frequently isolated species was C. al-
bicans (63%), followed by C. glabrata (13%), C. parapsilosis (10.2%), C. tropicalis 
(9.3%), and C. krusei (3.7%). One isolate each of C. kefyr, C. fabianii and C. incon-
spicua were detected. The percentage of C. albicans remained stable throughout the 
study period. The most frequent risk factors of Candida BSI in our patient popula-
tion were intensive care treatment (60.4%), abdominal surgery (52.5%), and solid 
malignancy (30.7%). All isolates were wild-type organisms, no acquired antifungal 
resistance was detected.
Keywords: Candida spp., bloodstream infection, epidemiology, antifungal 
susceptibility
Introduction
Candida spp. are a leading cause of bloodstream infection (BSI), associat-
ed with high mortality and increased hospital costs [1]. The annual incidence of 
Candida BSI varies greatly by region based on epidemiological studies from 
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 Europe and the USA: incidence ranges from 3.0 to 26.2 / 100 000 inhabitants. 
The incidence of Candida BSI in Denmark and Spain were similar (8.6 / 100 000 
inhabitants, and 8.1 / 100 000 inhabitants, respectively), while a much higher in-
cidence (26.2 / 100 000 inhabitants) was reported from Baltimore in the USA, 
and the incidence was the lowest in Norway (3.0 / 100 000 inhabitants) [2–6].
Risk factors of Candida BSI are well established, including treatment at 
the intensive care unit (ICU), broad-spectrum antibiotic therapy, abdominal sur-
gery, malignancy, the administration of total parenteral nutrition (TPN), the pres-
ence of intravenous catheters, mechanical ventilation, acute renal failure, immu-
nosuppressive treatment, neutropenia, and prior colonization with Candida spp. 
[7–12].
C. albicans remains the most frequently isolated species in most reports, 
but a shift towards non-albicans species has been detected [6, 13, 14]. The rise in 
the rate of fl uconazole non-susceptible Candida spp., mainly C. glabrata, has 
been linked with prior fl uconazole exposure [15, 16]. Reports of breakthrough 
Candida BSI and the isolation of multiresistant isolates, especially C. glabrata 
strains resistant to echinocandins, are alarming [17, 18].
The epidemiology of Candida BSIs varies greatly by region, therefore eval-
uation of local data is essential to assess local trends, identify patients at risk of 
infection, and to determine which antifungal drug is most adequate as empirical 
therapy. The aim of our study was to evaluate the epidemiology of Candida BSIs 
in the adult population at our institute, and to detect any strains with acquired 
antifungal resistance.
Materials and Methods
All episodes of candidaemia in patients over the age of 18 were analyzed 
during a fi ve-year period, from January 2010 to December 2014, at Semmelweis 
University, a 2250-bed tertiary hospital with 105 000 admissions per year. An 
episode of candidaemia was defi ned as isolation of Candida from blood culture 
on at least one occasion. Episodes were considered separate if they occurred 
more than 30 days apart, or different Candida species were isolated.
Patient data was collected retrospectively using a standardized case report 
form which included demographic data, underlying diseases, comorbidities (dia-
betes mellitus, organ failure, malignancy, immunosuppression), presence of in-
travascular devices, mechanical ventilation, administration of parenteral nutri-
tion, and isolate characteristics (Candida species, antifungal susceptibility 
profi le). Microbiological data, such as previous colonization by Candida spp., and 
time to blood culture positivity were also recorded.
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Blood samples were collected and processed using either the Bactec™ 9120 
(Beckton Dickinson) or BacT/ALERT® 3D (BioMérieux) automated blood cul-
ture systems. Isolates were identifi ed by phenotypic methods [carbohydrate as-
similation profi le obtained by the API 20C AUX system (BioMérieux), and mor-
phology of pseudohyphae on malt agar] and matrix-assisted laser desorption/
ionization time-of-fl ight mass spectrometry (MALDI-TOF/MS, Bruker) analysis. 
Routine antifungal susceptibility testing was performed by E-test® (BioMérieux) 
method, according to the manufacturer’s instructions. Minimal inhibitory con-
centration (MIC) results were interpreted according to EUCAST clinical break-
points [19].
Fisher’s exact test was used to assess if any of the risk factors of candidae-
mia had any connection with 30-day mortality and to describe changes in isolate 
incidence. A p value of <0.05 was considered signifi cant.
Results
Incidence
Candidaemia was detected in 129 cases in adult patients between 2010–
2014. The number of episodes per year and their incidence is presented in Table 
I. More than half (62%, n = 80) of the 129 episodes occurred in the ICU. Figure 1 
shows the distribution of candidaemia in the different departments.
Patient demographics and clinical characteristics
The mean age of patients was 62.8 years overall, and 60.1% were male. 
Eighty-three (64.8%) patients were admitted with a surgical diagnosis, and 55.5% 
of the patients had major abdominal surgery before the detection of candidaemia. 
Table I. Candidaemia in adult patients at Semmelweis University, 2010–2014
Number of episodes /  10 000 admissions
2010 18 1.7
2011 19 1.8
2012 27 2.57
2013 37 3.50
2014 28 2.66
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Among underlying diseases of Candida BSI, solid malignancy was the most 
prevalent (30.5%), followed by diabetes mellitus (24.2%), and immunosuppres-
sion (19.5%).
The mean time to blood culture positivity was 1.41 days overall (range 
0.37–5.64 days), with blood cultures containing C. glabrata requiring longer in-
cubation time to positivity (2.67 days on average, range 0.43–5.64) than the other 
species.
Previous colonization in at least one site by the same Candida sp. that was 
isolated from the bloodstream was detected in 99 episodes (77.3%). The sites of 
colonization were the respiratory tract (46.9%), the urinary tract (22.6%), an in-
travascular device (35.9%), and wounds (23.4%). The source of Candida BSI was 
identifi ed in 74 cases: four bloodstream isolates originated from the urinary tract, 
17 from an abdominal abscess or peritoneal infection, three from deep skin infec-
tions, three from the mediastinum, and one case of endocarditis was identifi ed. 
Forty-six (35.9%) episodes were associated with a central venous line. Demo-
graphic data and clinical characteristics are summarized in Table II.
Overall 30-day mortality was 50.8%, whereas 30-day mortality the highest 
(90.9%) with C. tropicalis BSI and the lowest with C. krusei (25%) and C. parap-
silosis (27.3%).
Univariate analysis was performed to assess if any risk factors of candidae-
mia could be associated with a higher mortality rate. No such connection was 
detected; p values are presented in Table III.
Isolate characteristics
A total of 136 isolates were collected. The most frequently isolated spe-
cies was C. albicans (63%), followed by C. glabrata (13%), C. parapsilosis 
(10.2%), C. tropicalis (9.3%), and C. krusei (3.7%). C. kefyr caused one episode 
Figure 1. Incidence of candidaemia (number of episodes per department) 
at Semmelweis University, 2010–2014
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in 2013, and C. fabianii and C. inconspicua caused one episode each in 2014. 
Seven cases (6.9%) of BSI with multiple Candida spp. were recorded. C. albicans 
and C. glabrata were isolated in four cases, C. albicans and C. parapsilosis in 
one case, C. albicans and C. tropicalis in one case, and C. parapsilosis and 
C. glabrata in one case.
There was no signifi cant change in the percentage of C. albicans per year 
(63% of all isolates) during the study period, but the rate of species with de-
creased susceptibility or resistance to fl uconazole increased from 10.5% in 2010 
to 39.3% in 2014 (p < 0.005). Figure 2 shows species distribution between 2010 
and 2014.
All isolates were wild-type organisms and no acquired resistance was 
 detected based on EUCAST breakpoints and available epidemiological cut-off 
values. The antifungal MIC range, MIC 50 and MIC 90 values are presented in 
Table IV.
Discussion
The incidence of Candida BSI at our institute increased between 2010 and 
2013 (R2 = 0.9) from 1.7 to 3.5 episodes / 10 000 admissions, in agreement with 
worldwide trends, but dropped back to 2.66 episodes / 10 000 admissions in 2014. 
The incidence rate is similar to previous Hungarian data and results from other 
European centers [20, 21, 22]. The decrease in incidence during the last study 
year may be explained by the administration of prophylactic antifungal therapy 
by clinicians after the problem of increasing rates of Candida BSI was detected.
C. albicans was the most frequently isolated species (63%), and the per-
centage of C. albicans isolates per year did not change signifi cantly during the 
study period. Several studies have detected a shift towards non-albicans Candida 
spp., especially C. glabrata, causing BSI [23]. This trend was observed at our 
institute as well, with the number of non-albicans isolates increasing steadily 
from 2010 to 2014. The number of C. glabrata isolates increased from 2 isolates 
in 2010 to 9 isolates in 2014.
Candidaemia was especially prevalent in patients in the ICU after abdomi-
nal surgery: the majority of our cases (60.9%) occurred in the ICU, and over half 
(55.5%) following major abdominal surgery. These fi ndings mirror the results of 
Kuhns et al., who in a survey of 47 707 cases determined that 20.7% of BSI in the 
ICU following abdominal surgery were caused by Candida spp. [24].
Solid malignancy was a major risk factor of candidaemia, present in 30.5% 
of the patients. Surveillance cultures are recommended in patients at risk to de-
tect colonization by Candida spp. [25], which precluded Candida BSI at our in-
stitute in 77.3% of cases.
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Table IV. Antifungal MIC range, MIC50 and MIC90 values of Candida bloodstream isolates 
at Semmelweis University, Hungary, 2010–2014
Species Antifungal agent MIC range (μg/ml) MIC50 (μg/ml) MIC 90 (μg/ml)
Candida albicans
(n = 75)
Fluconazole 0.064–1 0.25 0.5
Itraconazole 0.016–0.125 0.032 0.125
Voriconazole 0.004–0.064 0.008 0.064
Posaconazole 0.008–0.016 0.008 0.016
Anidulafungin 0.008–0.032 0.016 0.032
Micafungin 0.004–0.016 0.008 0.016
Caspofungin 0.004–0.032 0.008 0.032
Amphotericin B 0.064–0.5 0.25 0.5
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Table III. Risk factors of candidaemia vs. mortality (2010–2014, Semmelweis University, Hungary)
Recovered patient Fatal outcome p value
Abdominal surgery 27 24 0.2
Treatment at ICU 31 27 0.088
Solid malignancy 11 15 0.652
Acute leukaemia  4  3 0.7
Immunosuppression  8 12 0.617
Parenteral nutrition 11 11 0.808
Presence of an endovascular catheter 27 36 0.656
Figure 2. Species distribution of Candida bloodstream isolates at Semmelweis University, 
Hungary, 2010–2014
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Species Antifungal agent MIC range (μg/ml) MIC50 (μg/ml) MIC 90 (μg/ml)
Candida parapsilosis
(n = 11)
Fluconazole 0.064–1 0.125 0.5
Itraconazole 0.03–0.125 0.125 0.125
Voriconazole 0.004–0.064 0.016 0.032
Posaconazole 0.008–0.032 0.016 0.032
Anidulafungin 0.5–1.0 1 1
Micafungin 0.25–0.5 0.25 0.5
Caspofungin 0.064–0.25 0.125 0.25
Amphotericin B 0.125–0.5 0.25 0.5
Candida tropicalis
(n = 11)
Fluconazole 0.125–1 0.25 0.5
Itraconazole 0.016–0.125 0.064 0.125
Voriconazole 0.008–0.064 0.016 0.064
Posaconazole 0.008–0.032 0.016 0.032
Anidulafungin 0.008–0.016 0.016 0.016
Micafungin 0.008–0.032 0.016 0.032
Caspofungin 0.016–0.032 0.032 0.032
Amphotericin B 0.125–0.5 0.25 0.5
Candida glabrata
(n = 17)
Fluconazole 2.0–16 4 8
Itraconazole 0.064–0.25 0.125 0.25
Voriconazole 0.125–0.5 0.25 0.5
Posaconazole 0.5–1.0 1 1
Anidulafungin 0.016–0.03 0.03 0.03
Micafungin 0.004–0.016 0.08 0.016
Caspofungin 0.004–0.03 0.016 0.03
Amphotericin B 0.25–1.0 0.5 1
Candida krusei
(n = 4)
Fluconazole 16–32 32 32
Itraconazole 0.03–1.0 1 1
Voriconazole 0.032–1.0 0.064 1
Posaconazole 0.032–0.125 0.032 0.125
Anidulafungin 0.008–0.03 0.016 0.03
Micafungin 0.004–0.03 0.008 0.03
Caspofungin 0.016–0.03 0.016 0.03
Amphotericin B 0.25–0.5 0.25 0.5
Table IV. (cont.)
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Eight cases (6.25%) of BSI caused by more than one Candida spp. were 
detected. Polyfungal candidaemia is uncommon and has been associated with 
severe underlying disease, use of intravascular catheter, treatment at ICU, prior 
antibiotic exposure and heavy colonization with Candida spp. [26]. Signifi cant 
statistical results could not be achieved due to the small sample size, but patients 
with multiple Candida isolates suffered from solid malignant disease (37.5%), 
and received TPN more frequently (62.5%) compared with overall rates.
Acquired resistance to at least one group of antifungals has been detected 
in case of several Candida spp. Reports of multi-resistant C. glabrata isolates 
resistant to azoles, echinocandins and amphotericin B are especially alarming 
[27, 28]. All the isolates in our study were wild-type organisms, indicating that 
 acquired antifungal resistance of Candida spp. is not an issue in Hungary yet. 
The emergence of resistant isolates has been linked with prior antifungal treat-
ment. Echinocandin treatment has only recently been implemented in Hungarian 
routine clinical care, explaining why resistant isolates have not been detected yet. 
What is especially daunting is the fact that isolates resistant to echinocandins are 
frequently resistant to amphotericin B as well, posing a serious therapeutic chal-
lenge to clinicians.
The overall 30-day mortality rate at our institute was higher (50.8%) than 
fi gures reported in other European and US centers (22–37%) [29, 30]. Mortality 
rate by species was the highest for C. tropicalis (90.9%) and C. albicans (50.7%); 
these two species are the most virulent compared with other species and have 
been associated with higher mortality rates in BSI [31], though the mortality rate 
for C. tropicalis may be falsely high due to the small sample size.
No risk factors of Candida BSI were found to be signifi cantly associated 
with patient mortality.
This study describes the local epidemiology and antifungal susceptibility 
at a university hospital. The incidence of Candida BSI increased during the study 
period, and fl uconazole non-susceptible species became more prevalent. Rare 
Candida spp., such as C. fabianii and C. inconspicua were identifi ed as cause of 
BSI. No isolates with acquired antifungal resistance were detected. Surveillance 
of Candida BSI should be continued in the future to assess changes in epidemiol-
ogy and to monitor antifungal resistance.
Authors’ Contributions
PJ and KK conceived and designed the study. PJ collected and analysed the 
data. PJ and KK wrote and corrected the manuscript. JE and IM contributed in 
collecting the isolates and in correction of the manuscript.
 EPIDEMIOLOGY OF CANDIDAEMIA 327
Acta Microbiologica et Immunologica Hungarica 62, 2015
Confl ict of Interest
The authors declare that they have no competing interests.
References
1. Kett, D. H., Azoulay, E., Echeverria, P. M., Vincent, J. L., and for the Extended Prevalence 
of Infection in the ICU Study (EPIC II) Group of Investigators: Candida bloodstream 
 infections in intensive care units: Analysis of the extended prevalence of infection in 
 intensive care unit study. Crit Care Med 39, 665–670 (2011).
2. Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjaeld-
gaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., Rosenvinge, F. S., Røder, 
B., Schønheyder, H. C., Thomsen, M. K., Truberg, K.: National surveillance of fungemia 
in Denmark (2004 to 2009). J Clin Microbiol 49, 325–334 (2011).
3. Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., 
Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., Almirante, 
B.; CANDIPOP Project; GEIH-GEMICOMED (SEIMC); REIPI: Epidemiology and 
 predictive factors for early and late mortality in Candida bloodstream infections: A popu-
lation-based surveillance in Spain. Clin Microbiol Infect 20, 245–254 (2014).
4. Sandven, P., Bevanger, L., Digranes, A., Haukland, H. H., Mannsåker, T., Gaustad, P., and 
the Norwegian Yeast Study Group: Candidemia in Norway (1991 to 2003): Results from 
a nationwide study. J Clin Microbiol 44, 1977–1981 (2006).
5. Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., 
Magill, S. S., Derado, G., Park, B. J., Chiller, T. M.: Changes in incidence and antifun-
gal drug resistance in candidemia: Results from population-based laboratory surveil-
lance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis 55, 1352–1361 (2012).
6. Wisplinghoff, H., Ebbersa, J., Geurtza, L., Stefanik, D., Major, Y., Edmond, M. B., Wen-
zel, P., Seifert, H.: Nosocomial bloodstream infections due to Candida spp. in the USA: 
Species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob 
Agents 43, 78–81 (2014).
7. Tapia, G. G., Razonable, R. R., Eckel-Passow, J. E., Lahr, B. D., Afessa, B., Keegan, M. 
T., Catania, J., Baddour, L. M.: A scoring model of factors associated with Candida 
glabrata candidemia among critically ill patients. Mycoses 55, 228–236 (2012).
8. Chi, H. W., Yang, Y. S., Shang, S. T., Chen, K. H., Yeh, K. M., Chang, F. Y., Lin, J. C.: 
Candida albicans versus non-albicans bloodstream infections: The comparison of risk 
factors and outcome. J Microbiol Immunol Infect 44, 369–375 (2011).
9. Leenders, N. H., Oosterheert, J. J., Ekkelenkamp, M. B., De Lange, D. W., Hoepelman, A. 
I., Peters, E. J.: Candidemic complications in patients with intravascular catheters colo-
nized with Candida species: An indication for preemptive antifungal therapy? Int J In-
fect Dis 15, 453–458 (2011).
10. Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H. U., Quan, S. P., 
Horn, D.: Epidemiology and outcomes of candidemia in 3648 patients: Data from the 
Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Micro-
biol Infect Dis 74, 323–331 (2012).
328 PONGRÁCZ et al.
Acta Microbiologica et Immunologica Hungarica 62, 2015
11. Jordá-Marcos, R., Álvarez-Lerma, F., Jurado, M., Palomar, M., Nolla-Salas, J., León, M. 
A., León, C.; EPCAN Study Group: Risk factors for candidaemia in critically ill pa-
tients: A prospective surveillance study. Mycoses 50, 302–310 (2007).
12. Labelle, A. J., Micek, S. T., Roubinian, N., Kollef, M. H.: Treatment-related risk factors 
for hospital mortality in Candida bloodstream infections. Crit Care Med 36, 2967–
2972 (2008).
13. Hii, I. M., Chang, H. L., Lin, L. C., Lee, Y. L., Liu, Y. M., Liu, C. E., Chen, C. H., Cheng, 
Y. R., Chang, C. Y.: Changing epidemiology of candidemia in a medical center in middle 
Taiwan. J Microbiol Immunol Infect, http://dx.doi.org/10.1016/j.jmii.2013.08.017 (2013).
14. Ma, C. F., Li, F. Q., Shi, L. N., Hu, Y. A., Wang, Y., Huang, M., Kong, Q. Q.: Surveillance 
study of species distribution, antifungal susceptibility and mortality of nosocomial candi-
demia in a tertiary care hospital in China. BMC Infect Dis 13, 337 (2013).
15. Bassetti, M., Ansaldi, F., Nicolini, L., Malfatto, E., Molinari, M. P., Mussap, M., Rebesco, 
B., Bobbio Pallavicini, F., Icardi, G., Viscoli, C.: Incidence of candidaemia and relation-
ship with fl uconazole use in an intensive care unit. J Antimicrob Chemother 64, 625–
629 (2009).
16. Lee, I., Fishman, N. O., Zaoutis, T. E., Morales, K. H., Weiner, M. G., Synnestvedt, M., 
Nachamkin, I., Lautenbach, E.: Risk factors for fl uconazole-resistant Candida glabrata 
bloodstream infections. Arch Intern Med 169, 379–383 (2009).
17. Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., Alexander, B. 
D.: Breakthrough invasive Candidiasis in patients on micafungin. J Clin Microbiol 48, 
2373–2380 (2010).
18. Cho, E. J., Shin, J. H., Kim, S. H., Kim, H. K., Park, J. S., Sung, H., Kim, M. N., Im, H. J.: 
Emergence of multiple resistance profi les involving azoles, echinocandins and ampho-
tericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungae-
mia. J Antimicrob Chemother 70, 1268–1270 (2015).
19. The European Committee on Antimicrobial Susceptibility Testing. Antifungal Agents. 
Breakpoint tables for interpretation of MICs. Version 7.0, 2014. http://www.eucast.org.
20. Wille, M. P., Guimarães, T., Furtado, G. H., Colombo, A. L.: Historical trends in the epi-
demiology of candidaemia: Analysis of an 11-year period in a tertiary care hospital in 
Brazil. Mem Inst Oswaldo Cruz 108(3), 288–292 (2013).
21. Dóczi, I., Dósa, E., Hajdú, E., Nagy, E.: Aetology and antifungal susceptibility of yeast 
bloodstream infections in a Hungarian university hospital between 1996 and 2000. I Med 
Microbiol 51(8), 677–681 (2002).
22. Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Bi-
raghi, E., Canton, E., Zimmermann, K., Seaton, S., Grillot, R.; ECMM Working Group on 
Candidaemia: Epidemiology of candidaemiain Europe: Results of 28-month European 
Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J 
Clin Microbiol Infect Dis 23(4), 317–322 (2004).
23. Moretti, M. L., Trabasso, P., Lyra, L., Fagnani, R., Resende, M. R., de Oliveira Cardoso, 
L. G., Schreiber, A. Z.: Is the incidence of candidemia caused by Candida glabrata in-
creasing in Brazil? Five-year surveillance of Candida bloodstream infection in a univer-
sity reference hospital in southeast Brazil. Med Mycol 51(3), 225–230 (2013).
24. Kuhns, M., Rosenberger, A., Bader, O., Reichard, U., Gross, U., Weig, M.: Incidence of 
Candidaemia following abdominal surgery in German hospitals. Zentralbl Chir 2013 Nov 
15. [in German]
 EPIDEMIOLOGY OF CANDIDAEMIA 329
Acta Microbiologica et Immunologica Hungarica 62, 2015
25. Posteraro, B., De Pascale, G., Tumbarello, M., Torelli, R., Pennisi, M. A., Bello, G., Mav-
iglia, R., Fadda, G., Sanguinetti, M., Antonelli, M.: Early diagnosis of candidemia in in-
tensive care unit patients with sepsis: a prospective comparison of (1-3)-β-D-glucan assay, 
Candida score, and colonization index. Crit Care 15(5), R249 (2011).
26. Pulimood, S., Ganesan, L., Alangaden, G., Chandrasekar, P.: Polymicrobial candidemia. 
Diagn Microbiol Infect Dis 44(4), 353–357 (2002)
27. Cho, E. J., Shin, J. H., Kim, S. H., Kim, H. K., Park, J. S., Sung, H., Kim, M. N., Im, H. J.: 
Emergence of multiple resistance profi les involving azoles, echinocandins and ampho-
tericin B in Candida glabrata isolates from a neutropenia patient with prolonged fun-
gaemia. J Antimicrob Chemother 70(4), 1268–1270 (2015).
28. Cleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., 
Lockhart, S. R., Park, B. J.: Declining incidence of Candidemia and the shifting epide-
miology of candida resistance in two US metropolitan areas, 2008–2013: Results 
from population-based surveillance. PLoS One 10(3), e0120452 (2015).
29. Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H. U., Quan, S. P., 
Horn, D.: Epidemiology and outcomes of candidemia in 3648 patients: Data from the 
Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Micro-
biol Infect Dis 74, 323–331 (2012).
30. Das, I., Nightingale, P., Patel, M., Jumaa, P.: Epidemiology, clinical characteristics, and 
outcome of candidemia: Experiencein a tertiary referral center in the UK. Int J Infect Dis 
15(11), 759–763 (2011).
31. Arendrup, M., Horn, T., Frimodt-Møller, N.: In vivo pathogenicity of eight medically 
relevant Candida species in an animal model. Infection 30(5), 286–291 (2002).
